This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
« Back
Page 1 of 24

FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug!

By Adam Feuerstein

Sarepta Therapeutics received the green light from U.S. regulators to finally file a new drug application for eteplirsen, the company's experimental therapy for Duchenne muscular dystrophy.

04:42PM 05/19/15

An Open Letter to Sell-Sider Backtracking on Kite Pharma Questions

By Adam Feuerstein

There's nothing wrong with being a biotech bull who can also raise legitimate questions and understand risks.

12:48PM 05/19/15

Investors Get Teary Over Eleven Biotherapeutics' Dry-Eye Drug Failure

By Adam Feuerstein

Eleven Biotherapeutics' stock price is poised to plummet Monday in the wake of a late-stage study failure of an experimental drug to treat dry eye disease.

08:06AM 05/18/15

Amgen Indulges in Another Rheumatoid Arthritis Drug Price Increase

By Adam Feuerstein

The hike in Enbrel's list price pushed through by Amgen illustrates again how drug companies profit by raising the cost of their older medicines to offset falling prescription volume.

02:43PM 05/05/15

NewLink Insiders Sell Stock While Moss Grows on Pancreatic Cancer Vaccine Analysis

By Adam Feuerstein

The wait goes on for NewLink Genetics to disclose the second interim analysis from the ongoing phase III study of its pancreatic cancer vaccine.

10:40AM 05/05/15

Ariad Pharma CEO 'Retires' in Settlement With Activist Hedge Fund

By Adam Feuerstein

Sarissa Capital, which owns almost 7% of Ariad, started a proxy fight last February to wrest control of the board and force Berger's ouster.

09:01AM 04/29/15

Gilead Should Buy Vertex Pharma for $45B Now, Analyst Says

By Adam Feuerstein

Gilead Sciences should solve its long-term revenue cliff problem by acquiring Vertex Pharmaceuticals and its growing cystic fibrosis drug franchise for $45 billion, says Bernstein analyst Geoff Porges.

07:48AM 04/21/15

Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data

By Adam Feuerstein

Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.

10:22AM 04/20/15

If SpaceX CEO Musk was Biotech CEO, Rocket's 'Landing' Big Win

By Adam Feuerstein

In which Musk learns how to put a happy spin on failure from biotech CEOs.

09:07AM 04/16/15

Cancer Immunotherapy Remains Hot as Aduro Biotech Doubles in Value On IPO Debut

By Adam Feuerstein

Aduro Biotech shares doubled in value Wednesday following a successful initial public offering -- another sign that investor demand for cancer immunotherapy stocks remains strong.

11:35AM 04/15/15

« Back
Page 1 of 24

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs